Health Technology · Pharmaceuticals: Major · NSE: ALIVUS · data 2026-10-09
Alivus Life Sciences Ltd
Health check: Strong (8.2/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,326.3
Market cap
₹16,424 cr
P/E
27.1
P/B
—
ROE
18.4%
ROCE
22.4%
Debt / equity
0.02
Dividend yield
0.37%
1-year return
45.4%
52-week high
₹1,493.8
52-week low
₹819
Operating margin
29.3%
Growth
| Revenue (last 12 months) | ₹2,590 cr |
| Net profit (last 12 months) | ₹603 cr |
| Sales growth, 3 years (yearly) | 5.7% |
| Profit growth, 3 years (yearly) | 6.5% |
Chart patterns
- Descending triangle — forming (key level ₹1,317.6)
- Head and shoulders — forming (key level ₹1,317.6)
Similar companies
PFIZER LIMITED (PFIZER) · OneSource Specialty Pharma Limited (ONESOURCE) · Cohance Lifesciences Ltd (COHANCE) · Eris Lifesciences Ltd (ERIS) · Alembic Pharmaceuticals Limited (APLLTD)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALIVUS in NSE Scanner →